Cargando…

Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues

BACKGROUND: Cytochromes P450 (CYPs) constitute an enzyme family involved in the oxidative metabolism of a wide variety of endogenous and exogenous compounds, including anti-cancer drugs and carcinogens. Unlike other human CYPs, CYP4Z1 is highly expressed in human breast carcinoma and is associated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-saraireh, Yousef M, Alboaisa, Nafea S, Alrawashdeh, Hamzeh Mohammad, Hamdan, Omar, Al-Sarayreh, Sameeh, Al-Shuneigat, Jehad M, Nofal, Mohammad N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581338/
https://www.ncbi.nlm.nih.gov/pubmed/33144882
http://dx.doi.org/10.3332/ecancer.2020.1114
_version_ 1783598956972867584
author Al-saraireh, Yousef M
Alboaisa, Nafea S
Alrawashdeh, Hamzeh Mohammad
Hamdan, Omar
Al-Sarayreh, Sameeh
Al-Shuneigat, Jehad M
Nofal, Mohammad N
author_facet Al-saraireh, Yousef M
Alboaisa, Nafea S
Alrawashdeh, Hamzeh Mohammad
Hamdan, Omar
Al-Sarayreh, Sameeh
Al-Shuneigat, Jehad M
Nofal, Mohammad N
author_sort Al-saraireh, Yousef M
collection PubMed
description BACKGROUND: Cytochromes P450 (CYPs) constitute an enzyme family involved in the oxidative metabolism of a wide variety of endogenous and exogenous compounds, including anti-cancer drugs and carcinogens. Unlike other human CYPs, CYP4Z1 is highly expressed in human breast carcinoma and is associated with poor prognosis. As a result, CYP4Z1 was hypothesised to be a potential biomarker or drug target for the discovery and development of promising anti-cancer therapies. MATERIALS AND METHODS: CYP4Z1 expression was immunohistochemically studied in a set of 100 different human tissues, including normal, benign, malignant and metastatic tissues, which originated from 27 anatomical sites. As a tumour model for CYP4Z1 expression, a panel of different breast cancers was evaluated for CYP4Z1 expression and its relation to histopathological features and prognostic immunohistochemical markers. RESULTS: The immunohistochemical results revealed that CYP4Z1 was expressed in only one (4.3%) of the normal tissues from the mammary glands, while the expression of the enzyme was positive in 1 (11%), 12 (19%) and 2 (40%) of the benign, malignant and metastatic tissues, respectively. Interestingly, several tumour entities showed prominent expressions of CYP4Z1, including carcinomas of adrenal cortex, squamous cells of oesophagus, lung and cervix, as well as seminoma, astrocytoma, melanoma and lastly endometrial adenocarcinoma. In breast cancers, CYP4Z1 was expressed in 82% of the cases. Its expression was significantly associated with the pathology of tumour, histological grade and status of lymph node metastasis. Importantly, it was also significantly associated with the expressions of Her2, P53 and Ki-67. CONCLUSION: These findings greatly support future plans for the use of CYP4Z1 as a biomarker or target for anti-cancer drugs. However, large-scale validation studies are needed to better delineate the potential use of CYP4Z1 for therapeutic purposes.
format Online
Article
Text
id pubmed-7581338
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-75813382020-11-02 Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues Al-saraireh, Yousef M Alboaisa, Nafea S Alrawashdeh, Hamzeh Mohammad Hamdan, Omar Al-Sarayreh, Sameeh Al-Shuneigat, Jehad M Nofal, Mohammad N Ecancermedicalscience Research BACKGROUND: Cytochromes P450 (CYPs) constitute an enzyme family involved in the oxidative metabolism of a wide variety of endogenous and exogenous compounds, including anti-cancer drugs and carcinogens. Unlike other human CYPs, CYP4Z1 is highly expressed in human breast carcinoma and is associated with poor prognosis. As a result, CYP4Z1 was hypothesised to be a potential biomarker or drug target for the discovery and development of promising anti-cancer therapies. MATERIALS AND METHODS: CYP4Z1 expression was immunohistochemically studied in a set of 100 different human tissues, including normal, benign, malignant and metastatic tissues, which originated from 27 anatomical sites. As a tumour model for CYP4Z1 expression, a panel of different breast cancers was evaluated for CYP4Z1 expression and its relation to histopathological features and prognostic immunohistochemical markers. RESULTS: The immunohistochemical results revealed that CYP4Z1 was expressed in only one (4.3%) of the normal tissues from the mammary glands, while the expression of the enzyme was positive in 1 (11%), 12 (19%) and 2 (40%) of the benign, malignant and metastatic tissues, respectively. Interestingly, several tumour entities showed prominent expressions of CYP4Z1, including carcinomas of adrenal cortex, squamous cells of oesophagus, lung and cervix, as well as seminoma, astrocytoma, melanoma and lastly endometrial adenocarcinoma. In breast cancers, CYP4Z1 was expressed in 82% of the cases. Its expression was significantly associated with the pathology of tumour, histological grade and status of lymph node metastasis. Importantly, it was also significantly associated with the expressions of Her2, P53 and Ki-67. CONCLUSION: These findings greatly support future plans for the use of CYP4Z1 as a biomarker or target for anti-cancer drugs. However, large-scale validation studies are needed to better delineate the potential use of CYP4Z1 for therapeutic purposes. Cancer Intelligence 2020-09-29 /pmc/articles/PMC7581338/ /pubmed/33144882 http://dx.doi.org/10.3332/ecancer.2020.1114 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Al-saraireh, Yousef M
Alboaisa, Nafea S
Alrawashdeh, Hamzeh Mohammad
Hamdan, Omar
Al-Sarayreh, Sameeh
Al-Shuneigat, Jehad M
Nofal, Mohammad N
Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues
title Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues
title_full Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues
title_fullStr Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues
title_full_unstemmed Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues
title_short Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues
title_sort screening of cytochrome 4z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581338/
https://www.ncbi.nlm.nih.gov/pubmed/33144882
http://dx.doi.org/10.3332/ecancer.2020.1114
work_keys_str_mv AT alsarairehyousefm screeningofcytochrome4z1expressioninhumannonneoplasticpreneoplasticandneoplastictissues
AT alboaisanafeas screeningofcytochrome4z1expressioninhumannonneoplasticpreneoplasticandneoplastictissues
AT alrawashdehhamzehmohammad screeningofcytochrome4z1expressioninhumannonneoplasticpreneoplasticandneoplastictissues
AT hamdanomar screeningofcytochrome4z1expressioninhumannonneoplasticpreneoplasticandneoplastictissues
AT alsarayrehsameeh screeningofcytochrome4z1expressioninhumannonneoplasticpreneoplasticandneoplastictissues
AT alshuneigatjehadm screeningofcytochrome4z1expressioninhumannonneoplasticpreneoplasticandneoplastictissues
AT nofalmohammadn screeningofcytochrome4z1expressioninhumannonneoplasticpreneoplasticandneoplastictissues